5251 Edina Industrial Boulevard
Suite 575 Edina
Minneapolis, MN 55439
United States
952 405 6216
https://www.petvivo.com
Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 25
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. John Lai | CEO, President & Director | 312,65k | N/D | 1962 |
Mr. Randall A. Meyer | Chief Operating Officer | 245,41k | N/D | 1964 |
Mr. Garry N. Lowenthal | Chief Financial Officer | N/D | N/D | 1959 |
Mr. Randy Wenthold | Chief Science Officer | N/D | N/D | N/D |
Mr. John F. Dolan | General Counsel, Chief Business Development Officer & Secretary | 40,25k | N/D | 1965 |
Mr. Gary DeMel | Executive Vice President of Business Development | N/D | N/D | 1957 |
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
L'ISS Governance QualityScore di PetVivo Holdings, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.